FTC goes back to Teva on Cephalon deal

The Federal Trade Commission has requested additional information on Israel-based Teva Pharmaceutical Industries' planned acquisition of U.S. drugmaker Cephalon, potentially delaying regulatory clearance for another 30 days. Report